Education
About Us
Working with TipRanks
Follow Us
Molecular Templates, Inc. (MTEMQ)
:MTEMQ
MTEMQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $1.59
Previous CloseN/A
VolumeN/A
Average Volume (3M)9.78M
Market Cap
$658.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-168.84
Next Earnings
Aug 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,583,880
10 Day Avg. Volume221,309
30 Day Avg. Volume9,778,840
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
16.57%
Insiders
0.61%
Mutual Funds
<0.01% Other Institutional Investors
83.43% Public Companies and
Individual Investors
MTEMQ FAQ
What was Molecular Templates, Inc.’s price range in the past 12 months?
Molecular Templates, Inc. lowest stock price was $0.01 and its highest was $1.59 in the past 12 months.
What is Molecular Templates, Inc.’s market cap?
Molecular Templates, Inc.’s market cap is $658.00.
When is Molecular Templates, Inc.’s upcoming earnings report date?
Molecular Templates, Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 31 days.
How were Molecular Templates, Inc.’s earnings last quarter?
Currently, no data Available
Is Molecular Templates, Inc. overvalued?
According to Wall Street analysts Molecular Templates, Inc.’s price is currently Overvalued.
Does Molecular Templates, Inc. pay dividends?
Molecular Templates, Inc. does not currently pay dividends.
What is Molecular Templates, Inc.’s EPS estimate?
Molecular Templates, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Molecular Templates, Inc. have?
Molecular Templates, Inc. has 6,583,880 shares outstanding.
What happened to Molecular Templates, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Molecular Templates, Inc.?
Currently, no hedge funds are holding shares in MTEMQ
Company Description
Molecular Templates, Inc.
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.